-
Sales warning slams Ozempic maker Novo Nordisk's stock
-
Can Vonn defy ACL rupture to win Olympic medal?
-
Breakthrough or prelude to attack? What we know about Iran-US talks
-
German far-right MP detained over alleged Belarus sanctions breach
-
MSF says its hospital in South Sudan hit by government air strike
-
Merz heads to Gulf as Germany looks to diversify trade ties
-
Selection process for future Olympic hosts set for reform
-
Serbian minister on trial over Trump-linked hotel plan
-
UK PM says Mandelson 'lied', regrets appointing him US envoy
-
Cochran-Siegle tops first Olympic downhill training
-
Gaza health officials say strikes kill 21 after Israel says shots wounded officer
-
Injured Vonn's Olympic bid is 'inspirational', ski stars say
-
Albania arrests 20 for toxic waste trafficking
-
US-Africa trade deal renewal only 'temporary breather'
-
Mir sets pace on Sepang day two, Yamaha absent
-
Xi, Putin hail 'stabilising' China-Russia alliance
-
GSK boosted by specialty drugs, end to Zantac fallout
-
UK's ex-prince leaves Windsor home amid Epstein storm: reports
-
Sky is the limit for Ireland fly-half Prendergast, says captain Doris
-
Stocks fluctuate after Wall St AI-fuelled sell-off
-
Feyi-Waboso reminds England great Robinson of himself
-
Starmer faces MPs as pressure grows over Mandelson scandal
-
HRW urges pushback against 'aggressive superpowers'
-
Russia demands Ukraine give in as UAE talks open
-
Gaza civil defence says 17 killed in strikes after Israel says shots wounded officer
-
France's Kante joins Fenerbahce after Erdogan 'support'
-
CK Hutchison launches arbitration over Panama Canal port ruling
-
Stocks mostly rise as traders ignore AI-fuelled sell-off on Wall St
-
Acclaimed Iraqi film explores Saddam Hussein's absurd birthday rituals
-
On rare earth supply, Trump for once seeks allies
-
Ukrainian chasing sumo greatness after meteoric rise
-
Draper to make long-awaited return in Davis Cup qualifier
-
Can Ilia Malinin fulfil his promise at the Winter Olympics?
-
CK Hutchison begins arbitration against Panama over annulled canal contract
-
UNESCO recognition inspires hope in Afghan artist's city
-
Ukraine, Russia, US negotiators gather in Abu Dhabi for war talks
-
WTO must 'reform or die': talks facilitator
-
Doctors hope UK archive can solve under-50s bowel cancer mystery
-
Stocks swing following latest AI-fuelled sell-off on Wall St
-
Demanding Dupont set to fire France in Ireland opener
-
Britain's ex-prince Andrew leaves Windsor home: BBC
-
Coach plots first South Africa World Cup win after Test triumph
-
Spin-heavy Pakistan hit form, but India boycott risks early T20 exit
-
Japan eyes Premier League parity by aligning calendar with Europe
-
Whack-a-mole: US academic fights to purge his AI deepfakes
-
Love in a time of war for journalist and activist in new documentary
-
'Unprecedented mass killing': NGOs battle to quantify Iran crackdown scale
-
Seahawks kid Cooper Kupp seeks new Super Bowl memories
-
Thousands of Venezuelans march to demand Maduro's release
-
AI, manipulated images falsely link some US politicians with Epstein
Pfizer Covid pill preventing hospitalizations and deaths: White House
Pfizer's anti-Covid pill Paxlovid is helping stave off hospitalizations and deaths amid the United States' latest wave of infections, a senior White House official said Wednesday.
Demand for the treatment has soared, with a four-fold increase over the past month and an estimated 20,000 prescriptions being written every day, White House Covid-19 Response Coordinator Ashish Jha told reporters in a press call.
"I think that is actually a really important reason why, despite this very substantial increase in infections, we have not seen a commensurate increase in deaths," he said.
"We have seen hospitalizations rise, but again, not as much as one would have expected at this point, despite the fact that hospitalizations do lag. When you look at ICU care, the rate of ICU hospital admissions is much lower than what one would expect."
President Joe Biden's administration last month embarked on an aggressive push to expand access to the oral antiviral at tens of thousands of locations across the country.
Omicron's subvariants have driven daily new cases to 94,000, a three-fold increase over the last month, with hospitalizations running at 3,000 a day, and deaths at around 275.
Paxlovid, a combination of two drugs, both taken orally over five days, was shown in a clinical trial to reduce hospitalizations and deaths among at-risk people by almost 90 percent.
Concerns have been raised about "Paxlovid rebound" -- in which some patients clear the virus while on the treatment, but test positive after completing their course.
Jha said the government was studying the issue closely, "but I think it is not leading to people getting particularly sick." The rate of rebound during Paxlovid's clinical trial was two percent, but the dominant variant at the time was Delta.
He also encouraged doctors to adopt a "relatively permissive" approach to prescribing the medicine, given the broad eligibility criteria for being high risk.
"You should not get excessively restrictive, we have plenty of supply right now," he advised doctors.
Jha also urged Congress to quickly provide $22.5 billion in Covid funding so that the government could ensure the supply of next generation Covid vaccines, which are expected to protect against multiple variants.
"Other countries are in conversations with the manufacturers and starting to advance their negotiations," he said, warning Americans could be left behind.
If Congress failed to provide funding, "I think it'd be terrible, I think we'd see a lot of unnecessary loss of life if that were to happen," he said, but the Biden administration would try to find a way to provide vaccines to those at highest risk, he added.
X.Habash--SF-PST